DOTmed Home MRI Oncology Ultrasound Molecular Imaging X-Ray Cardiology Health IT Business Affairs
News Home Parts & Service Operating Room CT Women's Health Proton Therapy Endoscopy HTMs Mobile Imaging
SEARCH
Current Location:
>
> This Story


Log in or Register to rate this News Story
Forward Printable StoryPrint Comment
advertisement

 

advertisement

 

Business Affairs Homepage

Robert Sledd Owens & Minor names board member, chairman and interim president and CEO

Clinical wearables – remaining competitive in an evolving market Insights from Ravi Kuppuraj, Business Leader of Connected Sensing Venture for Philips

Daniel Kelsey AHRA hires chief executive officer

Driving premium platform valuations for future growth The radiology M&A market is red hot, help investors see the value in your business

TIAA Bank acquires $1.5 billion portfolio from GE Capital's HEF business Portfolio of healthcare equipment leases and loans

Veritas Capital, Evergreen Coast Capital to take athenahealth for $5.7 billion Gives athenahealth stock holders $135 in cash per share

A look into the medical device design process Go behind the scenes to see what factors contribute to the design of new medical devices

How hassle maps can improve radiology department operations Tips for finding and addressing friction points and improving overall patient care in radiology

When radiologists speak up, follow-up imaging improves Study supports better communication between radiologists and referring clinicians

Dr. Jonathan Luchs Premier Radiology Services appoints chief medical officer

Hologic has agreed to
acquire Focal Therapeutics

Hologic to acquire Focal Therapeutics for $125 million

by John R. Fischer , Staff Reporter
Hologic Inc. is furthering its expansion into the market of breast conservation surgery with the acquisition of Focal Therapeutics.

The women’s health manufacturer, agreed this week to purchase the privately held company, putting down $125 million in cash to secure the agreement, which adds Focal’s BioZorb marker product to the Hologic Breast Health product portfolio. The acquisition of Focal comes less than two months after the acquisition of Faxitron Optics for approximately $85 million.

Story Continues Below Advertisement

RamSoft PowerServer™ RIS/PACS - Enabling Efficient Diagnostic Imaging

RamSoft's PowerServer™ RIS/PACS is an intuitive, single database application that enables healthcare practices to operate diagnostic imaging more efficiently than ever before.Why is this important? Click to find out.



“Focal Therapeutics has commercialized an innovative marker that improves the standard of care for breast cancer patients by creating a permanent, three-dimensional indicator of the surgical site,” Jane Mazur, vice president of divisional communications at Hologic, told HCB News. “Coupled with our recent acquisition of Faxitron, BioZorb further expands our ability to help women diagnosed with breast cancer from screening through surgery.”

Placed by a surgeon, the implantable three-dimensional marker helps clinicians overcome challenges associated with breast conserving surgery, or lumpectomy by marking the tumor excision site for monitoring and future treatments.

The small coil product is composed of six titanium clips arranged in a 3D pattern that is implanted into the breast by the surgeon as the tumor is removed. There, the 3D pattern marks the tumor site, with the coil dissolving over time as the breast tissue heals and the open design of the product allows for tissue in-growth to take place during the healing process.

Expected to close in early October, the acquisition is estimated to be neutral to Hologic’s non-GAAP earnings per share in fiscal 2018 and accretive thereafter, adding to Hologic’s revenue growth rate and gross margin while broadening its recurring revenue base. It is expected to provide an attractive return on invested capital.

"The addition of Focal will further expand Hologic’s offerings and its long-standing commitment to early cancer detection," said Mazur. "It will enable Hologic to play a larger role in breast conserving surgery and widen the company’s position in the continuum of breast care."

The acquisition of Focal Therapeutics, which racked up approximately $16 million in revenue over the last 12 months, pairs BioZorb with solutions acquired from Faxitron, which include VisionCT, the first 3D breast specimen-designated CT systems designed and FDA approved to offer 360-degree images of excised lesions; and VersaVision digital specimen radiography system, cleared in October by the FDA for imaging core biopsy and surgically excised specimen samples.

Back to HCB News
  Pages: 1

Business Affairs Homepage


You Must Be Logged In To Post A Comment

Advertise
Increase Your
Brand Awareness
Auctions + Private Sales
Get The
Best Price
Buy Equipment/Parts
Find The
Lowest Price
Daily News
Read The
Latest News
Directory
Browse All
DOTmed Users
Ethics on DOTmed
View Our
Ethics Program
Gold Parts Vendor Program
Receive PH
Requests
Gold Service Dealer Program
Receive RFP/PS
Requests
Healthcare Providers
See all
HCP Tools
Jobs/Training
Find/Fill
A Job
Parts Hunter +EasyPay
Get Parts
Quotes
Recently Certified
View Recently
Certified Users
Recently Rated
View Recently
Certified Users
Rental Central
Rent Equipment
For Less
Sell Equipment/Parts
Get The
Most Money
Service Technicians Forum
Find Help
And Advice
Simple RFP
Get Equipment
Quotes
Virtual Trade Show
Find Service
For Equipment
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2018 DOTmed.com, Inc.
ALL RIGHTS RESERVED